+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Asia-Pacific Cardiac Biomarker Market 2019-2025

  • PDF Icon


  • January 2020
  • Region: Asia Pacific
  • Orion Market Research Private Limited
  • ID: 4901025
Asia-Pacific Cardiac biomarker Market Size, Share & Trends Analysis Report by Type (Creatine kinase (CK-MB), Troponins(T, I), Myoglobin, Natriuretic peptides (BNP & NT-PROBNP), Ischemia modified albumin and Others), By Application (Myocardial infraction, Congestive Heart Failure, Acute coronary syndrome, Atherosclerosis, and Others), By Location of Testing(Laboratory testing and Point of care testing) and Forecast 2019-2025.

Asia-Pacific cardiac biomarker market is estimated to grow significantly at a CAGR of around 7.1% during the forecast period. The Asia-Pacific has a potential market in cardiac biomarkers due to various factors such as rising healthcare spending, improving infrastructure& economy, and rising standards of living. China, India, Japan, Australia, Korea, and Taiwan are the key regions growing at a significant rate in the region. The healthcare systems in the region are improving significantly and expected to contribute to the cardiac biomarker market. The reason behind the potetial market is the support from government organizations and funding and investment in the cardiac biomarker research. In addition, the presence of key players contributes to the market growth of the cardiac biomarker in Asia-Pacific.

The market is segmented on the basis of type, application, and location of testing. Based on type, the market is segregated into Creatine kinase (CK-MB), Troponins (T, I), Myoglobin, Natriuretic peptides (BNP & NT-PROBNP), Ischemia modified albumin and Others. The troponin is anticipated to be the fastest growing and has a considerable market share in the Asia-Pacific cardiac biomarker market due to easy and high sensitivity that results in the high adoption of the test. Based on application, the market is segmented into myocardial infraction, congestive heart failure, acute coronary syndrome, atherosclerosis, and others. On the basis of the location of testing, the market is classified into laboratory testing and point of care testing.

The companies which are contributing to the growth of the Asia-Pacific cardiac biomarker market include Abbott Laboratories, BioMérieux S.A., Cisbio Bioassays SAS, Danaher Corp., F. Hoffmann-La Roche AG, HyTest Ltd, Merck KGaA, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market.

Research Methodology

The market study of Asia-Pacific cardiac biomarker market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The research team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. the analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for biotechnology companies, research institutes, hospitals, and government organizations for the overall market and competitive analysis. The report provides an in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:

1. Asia-Pacific Cardiac biomarker Market Research and Analysis by Type
2. Asia-Pacific Cardiac biomarker Market Research and Analysis by Application
3. Asia-Pacific Cardiac biomarker Market Research and Analysis by Location of Testing

The Report Covers:
  • Comprehensive research methodology of the Asia-Pacific cardiac biomarker market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Asia-Pacific cardiac biomarker market.
  • Insights about market determinants which are stimulating the Asia-Pacific cardiac biomarker market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Asia-Pacific Cardiac Biomarker Market by Type
5.1.1. Creatine kinase (CK-MB)
5.1.2. Troponins(T,I)
5.1.3. Myoglobin
5.1.4. Natriuretic peptides (BNP & NT-PROBNP)
5.1.5. Ischemia modified albumin
5.1.6. Others
5.2. Asia-Pacific Cardiac Biomarker Market by Application
5.2.1. Myocardial infraction
5.2.2. Congestive heart failure
5.2.3. Acute coronary syndrome
5.2.4. Atherosclerosis
5.2.5. Others
5.3. Asia-Pacific Cardiac Biomarker Market by Location of Testing
5.3.1. Laboratory testing
5.3.2. Point of care testing
6. Regional Analysis
6.1. China
6.2. India
6.3. Japan
6.4. Rest of Asia-Pacific
7. Company Profiles
7.1. Abbott Laboratories
7.2. BioMérieux S.A.
7.3. Cisbio Bioassays SAS
7.4. Danaher Corp.
7.5. F. Hoffmann-La Roche AG
7.6. HyTest Ltd.
7.7. Merck KGaA
7.8. Randox Laboratories Ltd.
7.9. Siemens Healthcare GmbH
7.10. Thermo Fisher Scientific Inc.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbott Laboratories
  • BioMérieux S.A.
  • Cisbio Bioassays SAS
  • Danaher Corp.
  • F. Hoffmann-La Roche AG
  • HyTest Ltd.
  • Merck KGaA
  • Randox Laboratories Ltd.
  • Siemens Healthcare GmbH
  • Thermo Fisher Scientific Inc.